News

MyChesCo on MSN2d
FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis
On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...
MPR2d
Imaavy Approved for Generalized Myasthenia Gravis
Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.
Managed Healthcare Executive3d
FDA Approves Imaavy for Long Term Treatment of Generalized Myasthenia Gravis
Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.
Contract Pharma3d
J&J’s IMAAVY Approved by FDA for Treatment of Generalized Myasthenia Gravis
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...
BioSpace3d
J&J Steps Into Crowded Myasthenia Gravis Market With FDA Nod
Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...
Pharmaceutical Technology on MSN3d
FDA approves J&J’s Imaavy for generalised myasthenia gravis
Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...
Medscape4d
FDA Approves New Monoclonal Antibody for Myasthenia Gravis
The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...
BioWorld4d
With FDA approval, J&J enters the myasthenia gravis fray
The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that has plenty of competition. The human Fc receptor ...
Healio4d
FDA approves Imaavy for generalized myasthenia gravis in patients aged 12 years and older
The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...